Biweekly TAS-102 with Bevacizumab combination study

Not Applicable

• Conditions: metastatic colorectal carcinoma

• Registration Number: JPRN-UMIN000029198
• Lead Sponsor: PO Epidemiological and Clinical Research Information Network(ECRIN)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-28
• Study Completion: 2019-11-06
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Not provided

Exclusion Criteria

1. any of the following complication: a. synchronous active malignancies other than carcinoma in situ or mucosal cancer b. central nervous system metastases c. active infection d. uncontrolled ascites, pleural effusion, pericardial effusion e. bowel obstruction, renal failure, liver failure, effusion f. uncontrolled DM g. uncontrolled hypertension h. symptomatic heart disease within 12 months i. active gastrointestinal bleeding j. uncontrolled HIV infection, HBV infection, HCV infection k. immunodeficency l. sever mental disorder 2. any of the following treatment: a. thoracotomy, or intestinal resection within 4 weeks b. chemotherapy within 1 week c. extensive radiotherapy d. investigational new drug within 1 week 3. history of TAS-102 4. grade 2 or more adverse events not recovered 5. transfusion within 7 days 6. urine dipstick for proteinuria more than +2 7. severe thrombosis or severe pulmonary disease 8. unhealed wound 9. hemorrhagic diathesis 10. pregnant and lactating females 11. patients judged by the investigator as unfit to be enrolled in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified